Sugarman-Brozan says FDA is neglecting enforcement

Share this article:
Prescription Access Litigation project director Alex Sugarman-Brozan told the Third Annual FDA Regulatory Symposium at Harvard in August that the agency is neglecting to enforce regulations on DTC advertising and needs to crack down on drug companies with more and earlier enforcement letters and hefty fines on offending companies, per pending regs.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.